Gu Xiao-Bin, Tian Tian, Tian Xiao-Jing, Zhang Xiao-Jun
Cancer Center, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China.
Nanlou Department of Respiratory Disease, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China.
Sci Rep. 2015 Jul 24;5:12493. doi: 10.1038/srep12493.
Published data on the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in non-small cell lung cancer (NSCLC) are controversial. We performed a meta-analysis to more accurately assess its prognostic value. The analysis was performed based on the data from 14 studies with 3,656 patients to estimate the correlation between NLR and overall survival (OS) and progression-free survival (PFS) in NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) were calculated to estimate the effect. We also conducted subgroup analysis and meta-regression analysis. The results demonstrated that elevated pretreatment NLR predicted poorer OS (HR: 1.70, 95% CI: 1.39-2.09) and PFS (HR: 1.63, 95% CI: 1.27-2.09) in patients with NSCLC. Subgroup analysis indicated that cut-off value of 5 showed consistently prognostic value. There was no significant heterogeneity or publication bias for OS and PFS for included studies. This meta-analysis revealed that elevated pretreatment NLR might be a predicative factor of poor prognosis for NSCLC patients.
已发表的关于中性粒细胞与淋巴细胞比值(NLR)在非小细胞肺癌(NSCLC)中的预后意义的数据存在争议。我们进行了一项荟萃分析,以更准确地评估其预后价值。该分析基于14项研究的3656例患者的数据,以估计NLR与NSCLC患者总生存期(OS)和无进展生存期(PFS)之间的相关性。计算95%置信区间(CI)的风险比(HR)以评估效应。我们还进行了亚组分析和meta回归分析。结果表明,治疗前NLR升高预示NSCLC患者的OS(HR:1.70,95%CI:1.39 - 2.09)和PFS(HR:1.63,95%CI:1.27 - 2.09)较差。亚组分析表明,临界值为5时具有一致的预后价值。纳入研究的OS和PFS不存在显著的异质性或发表偏倚。这项荟萃分析表明,治疗前NLR升高可能是NSCLC患者预后不良的一个预测因素。